Emergent BioSolutions Partners with Rocketvax to Develop Next-Gen Vaccines and Therapies

• Emergent BioSolutions Inc. has announced a strategic financial investment in Swiss Rockets Ltd, the parent company of Rocketvax Ltd, to support research and infrastructure development.

• The partnership includes plans for Emergent to lead the U.S. manufacturing and commercialisation of four Rocketvax pipeline candidates targeting infectious diseases, cancer, and autoimmune disorders.

Emergent BioSolutions Inc. has entered into an agreement to invest in Swiss Rockets Ltd, supporting research, infrastructure expansion, and biotech innovation. Swiss Rockets is the parent company of Rocketvax Ltd, a Swiss-based next-generation vaccine developer. The investment aligns with Emergent’s strategy to drive growth and transformation while advancing medical technologies.

As part of the agreement, Emergent will lead the U.S. manufacturing and commercialisation of four Rocketvax pipeline candidates. These candidates target infectious diseases, cancer, and autoimmune disorders. One of them is already part of a collaboration between Rocketvax and the U.S. National Institutes of Health (NIH) under the Project NextGen initiative. This initiative aims to develop next-generation vaccines, including a clinical trial using Rocketvax’s proprietary technology.

Among Rocketvax’s most advanced candidates is a live-attenuated nasal spray SARS-CoV-2 vaccine, which has shown superior efficacy compared to mRNA COVID-19 vaccines in animal studies. Live-attenuated vaccines are designed to trigger a broader and longer-lasting immune response, including mucosal immunity, which is crucial for respiratory infections.

Joe Papa, President and CEO of Emergent, stated: “We are excited to partner with Rocketvax to accelerate the development of innovative products that address significant public health challenges. As Rocketvax is poised to progress its pipeline, we will stand ready to leverage our unique capabilities to ultimately bring these solutions to patients and communities in need.”

Dr. Vladimir Cmiljanovic, CEO of Rocketvax Ltd, highlighted the significance of the collaboration, stating that it represents a transformative step for the company and the wider biotech sector. He emphasised that by working with Emergent, Rocketvax can harness its expertise in production and regulatory processes to advance next-generation vaccines. He added that the partnership is a major milestone in the company’s mission to develop breakthrough solutions for disease prevention and immunotherapy.